Telomeres and biological ageing in cardiovascular disease;Telomeren en biologische veroudering bij hart- En vaatziekten

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 22, 2008, Pages 1265-1270

  Huzen, J ^a   Van Veldhuisen, D J ^a   Van Gilst, W H ^a   Van Der Harst, P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIVISION; DNA STRAND BREAKAGE; ENVIRONMENTAL FACTOR; HEART FAILURE; HEREDITY; HUMAN; LEUKOCYTE; ONSET AGE; PATHOGENESIS; RELIABILITY; RISK FACTOR; TELOMERE;

AGE OF ONSET; AGING; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS; TELOMERE;

EID: 44949234660     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.
2. Njajou OT, Cawthon RM, Damcott CM, Wu SH, Ott S, Garant MJ, et al. Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci USA. 2007;104:12135-9.
3. Serra V, Grune T, Sitte N, Saretzki G, von Zglinicki T. Telomere length as a marker of oxidative stress in primary human fibroblast cultures. Ann N Y Acad Sci. 2000;908:327-30.
4. Von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med. 2005;5:197-203.
5. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503-14.
6. Blackburn EH. Switching and signaling at the telomere. Cell. 2001;106:661-73.
7. Saretzki G, Sitte N, Merkel U, Wurm RE, von Zglinicki T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene. 1999;18:5148-58.
8. De Meyer T, Rietzschel ER, de Buyzere ML, de Bacquer D, van Criekinge W, de Backer GG, et al. Paternal age at birth is an important determinant of offspring telomere length. Hum Mol Genet. 2007;16:3097-102.
9. Allsopp RC, Harley CB. Evidence for a critical telomere length in senescent human fibroblasts. Exp Cell Res. 1995;219:130-6.
10. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science. 2007;315:1850-3.
11. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I, et al. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood. 2006;107:2680-5.
12. Montanaro L, Chillà A, Trerè D, Pession A, Govoni M, Tazzari PL, et al. Increased mortality rate and not impaired ribosomal biogenesis is responsible for proliferative defect in dyskeratosis congenita cell lines. J Invest Dermatol. 2002;118:193-8.
13. Röth A, Dürig J, Himmelreich H, Bug S, Siebert R, Dührsen U, et al. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia. 2007;21:2456-62.
14. Panossian LA, Porter VR, Valenzuela HF, Zhu X, Reback E, Masterman D, et al. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging. 2003;24:77-84.
15. Harst P van der, Steege van der G, Boer RA de, Voors AA, Hall AS, Mulder MJ, et al. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. MERIT-HF Study Group. J Am Coll Cardiol. 2007;49:1459-64.
16. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361:393-5.
17. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet. 2001;358:472-3.
18. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23:842-6.
19. Starr JM, McGurn B, Harris SE, Whalley LJ, Deary IJ, Shiels PG. Association between telomere length and heart disease in a narrow age cohort of older people. Exp Gerontol. 2007;42:571-3.
20. Kurz DJ, Kloeckener-Gruissem B, Akhmedov A, Eberli FR, Bühler I, Berger W, et al. Degenerative aortic valve stenosis, but not coronary disease, is associated with shorter telomere length in the elderly. Arterioscler Thromb Vasc Biol. 2006;26:6114-7.
21. Martin-Ruiz CM, Gussekloo J, Heemst D van, von Zglinicki T, Westendorp RG. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell. 2005;4:287-90.
22. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002;105:1541-4.
23. Fuster JJ, Andrés V. Telomere biology and cardiovascular disease. Circ Res. 2006;99:1167-80.
24. Benetos A, Gardner JP, Zureik M, Labat C, Xiaobin L, Adamopoulos C, et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension. 2004;43:182-5.
25. Imanishi T, Hano T, Nishio I. Estrogen reduces endothelial progenitor cell senescence through augmentation of telomerase activity. J Hypertens. 2005;23:1699-706.
26. Bekaert S, de Meyer T, Rietzschel ER, de Buyzere ML, de Bacquer D, Langlois M, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Asklepios investigators. Aging Cell. 2007;6:639-47.
27. Gardner JP, Li S, Srinivasan SR, Chen W, Kimura M, Lu X, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005;111:2171-7.
28. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet. 2007;369:107-14.
29. Harst P van der, Voors AA, Volbeda M, Buikema H, Veldhuisen DJ van, Gilst WH van. Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. Am J Cardiol. 2006;97:1697-701.
30. Harst P van der, Voors AA, Gilst WH van, Böhm M, Veldhuisen DJ van. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res. 2006;71:443-54.
31. Spyridopoulos I, Haendeler J, Urbich C, Brummendorf TH, Oh H, Schneider MD, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation. 2004;110:3136-42.